Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Surgery is a large payment once. Medication is a smaller payment that never stops. That framing is where most people start, and it is roughly correct.
What most comparisons get wrong is the effectiveness side, because surgery and drug trials do not measure weight loss the same way. Once you understand that, the comparison changes.
The measurement problem
This single point explains most of the confusion in this debate.
Bariatric surgery results are usually reported as percentage excess weight loss (%EWL). Excess weight means the amount above a defined ideal weight. If you weigh 120 kg and your ideal is 70 kg, your excess is 50 kg. Losing 30 kg of that is 60 %EWL.
GLP-1 drug trials report percentage total body weight loss (%TWL). Losing 30 kg from 120 kg is 25 %TWL.
Same 30 kg. Two very different numbers.
So when someone compares surgery's "58 percent" against semaglutide's "15 percent," they are comparing two different measures and the gap looks far larger than it is.
The honest comparison
A systematic review and meta-analysis of long-term outcomes, published on PubMed, examined weight loss at 10 or more years across bariatric procedures.
Gastric bypass produced a weighted mean of 56.7 %EWL and sleeve gastrectomy 58.3 %EWL at ten or more years. Critically, the same analysis noted sleeve gastrectomy produced total body weight loss above 20 percent at 10+ years.
That 20+ %TWL figure is the one to compare against drug trials.
| Treatment | Total body weight loss | Timeframe |
|---|---|---|
| Sleeve gastrectomy | >20 percent | 10+ years |
| Tirzepatide 15 mg | 20.9 percent | 72 weeks |
| Semaglutide 2.4 mg | 14.9 percent | 68 weeks |
Tirzepatide's 20.9 percent in SURMOUNT-1 is genuinely comparable to surgery's long-term total weight loss.
That is a remarkable development in obesity treatment, and it is far more interesting than the misleading 58-versus-15 comparison.
The crucial difference is duration. Surgery's result was measured at ten years and beyond. Tirzepatide's was measured at 72 weeks, on continuous medication. Nobody knows what tirzepatide looks like at ten years, and weight regain after stopping is well documented.
Surgery is a permanent anatomical change. Medication works while you take it.
The cost structures
Surgery is a large single payment. In Pakistan, private bariatric procedures involve surgeon fees, anaesthesia, hospital stay, pre-operative workup and post-operative follow-up. It is a substantial sum, paid mostly at once.
It also carries ongoing costs people underestimate: lifelong vitamin and mineral supplementation, periodic blood monitoring for deficiencies, and follow-up appointments.
Medication is a recurring cost with no end point. Imported GLP-1 injections run Rs 20,000 to Rs 50,000 monthly here, plus consultation, cold chain and monitoring.
The arithmetic that matters is the crossover. At those monthly figures, medication costs accumulate quickly. Over several years, ongoing GLP-1 medication can exceed the one-time cost of surgery.
That comparison only holds if you can obtain the medication continuously, which in Pakistan is the weak link.
What surgery involves that medication does not
Permanent anatomical change. Sleeve gastrectomy removes most of the stomach. This cannot be reversed.
Surgical risk. Bleeding, leaks, infection, blood clots and anaesthetic complications are real, and mortality risk, while low in experienced centres, is not zero.
Nutritional consequences. Reduced absorption means lifelong supplementation. Deficiencies in iron, B12, vitamin D, calcium and folate are common and need monitoring.
Dumping syndrome, particularly after bypass, where sugary food causes cramping, nausea, sweating and diarrhoea.
Follow-up requirements that continue indefinitely.
Psychological adjustment. Rapid dramatic weight loss changes body image, relationships and identity in ways that need support.
What medication involves that surgery does not
It stops working when you stop. This is the central difference. Appetite returns and weight regain is common.
Ongoing cost with no end.
Supply dependency, which in Pakistan means an import chain that frequently breaks.
Side effects for the duration, chiefly nausea, vomiting, diarrhoea and constipation.
No anatomical safety net. Surgery restricts intake physically whether or not you feel hungry.
Which suits whom
Surgery is generally considered for BMI 40 and above, or 35 and above with serious weight-related conditions such as type 2 diabetes, sleep apnea or severe joint disease, in people who have tried other approaches and can commit to lifelong follow-up.
Medication generally suits BMI 30 and above, or 27 and above with a weight-related condition, in people who want to avoid surgery and can sustain treatment.
Increasingly the two are not alternatives. GLP-1 medication is used before surgery to reduce operative risk, and after surgery to manage regain.
The Pakistan reality
Both options face barriers here.
Bariatric surgery is available in Pakistan at private hospitals in Karachi, Lahore and Islamabad, with experienced surgeons. It is expensive but it is genuinely obtainable, and it is a single decision rather than an ongoing supply problem.
GLP-1 medication is not registered in any form, so every pen arrives through import, at unregulated prices, with no authenticity verification and frequent supply interruption.
That is an unusual situation. In most countries medication is the more accessible option and surgery the harder one. Here, surgery is arguably the more reliably obtainable of the two.
Before considering either, check your BMI, since eligibility for both is anchored to it.
Where the middle ground sits
Most people searching this comparison are not candidates for surgery and cannot sustain imported injections. That gap is real and it is where locally registered options fit.
A registered GLP-1 sublingual supplement is a different category from both. METASLIM™ works on the GLP-1 appetite pathway with a physician reviewing every order before dispatch, made to a consistent, GMP-manufactured standard. It is not surgery and not a pharmaceutical GLP-1 receptor agonist, so neither the 20 %TWL surgical figure nor SURMOUNT-1 results describe it.
What it offers is something obtainable and supervised for people whose BMI does not warrant surgery and whose budget will not sustain eighteen months of imported injections.
Our monthly cost comparison sets the medication figures side by side, and Zepbound cost explained covers the strongest injectable.
The summary
Surgery reports excess weight loss, drug trials report total body weight loss. Comparing them directly overstates the gap.
On total body weight loss, sleeve gastrectomy exceeded 20 percent at ten or more years. Tirzepatide produced 20.9 percent at 72 weeks. Those are genuinely comparable figures over very different timeframes.
Surgery is a large one-off cost with lifelong supplementation and follow-up. Medication is a recurring cost that stops working when you stop paying.
Over several years, ongoing GLP-1 costs can exceed the one-time cost of surgery.
In Pakistan, surgery is arguably more reliably obtainable than imported injections, which is the reverse of most countries.
See if you qualify for the program if neither extreme fits your situation.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.